1984-27-6

Basic information

• Product Name: 4-BROMO-N-ISOPROPYLBENZENESULPHONAMIDE
• Synonyms: 4-BROMO-N-ISOPROPYLBENZENESULPHONAMIDE;p-bromo-n-isopropyl-benzenesulfonamid;N-ISOPROPYL 4-BROMOBENZENESULFONAMIDE;4-Bromo-N-isopropylbenzenesulphonamide 98%;N-Isopropyl-p-bromobenzenesulfonamide;4-bromo-N-isopropyl-benzenesulfonamide;4-bromo-N-propan-2-ylbenzenesulfonamide;4-bromo-N-propan-2-yl-benzenesulfonamide
• CAS NO: 1984-27-6
• Molecular Formula: C₉H₁₂BrNO₂S
• Molecular Weight: 278.17
• Product Categories: blocks;Bromides;Sulfonamides
• Mol File: 1984-27-6.mol
• Article Data: 11

Chemical Properties

• Melting Point: 87-89
• Boiling Point: 348.4 °C at 760 mmHg
• Flash Point: 164.5 °C
• Appearance: /
• Density: 1.467 g/cm³
• Vapor Pressure: 5.05E-05mmHg at 25°C
• Refractive Index: 1.554
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 11.48±0.50(Predicted)
• CAS DataBase Reference: 4-BROMO-N-ISOPROPYLBENZENESULPHONAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-N-ISOPROPYLBENZENESULPHONAMIDE(1984-27-6)
• EPA Substance Registry System: 4-BROMO-N-ISOPROPYLBENZENESULPHONAMIDE(1984-27-6)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 1984-27-6(Hazardous Substances Data)

Usage

Uses

4-Bromo-N-isopropylbenzenesulfonamide is a benzenesulfonamide derivative used as an intermediate in organic synthesis and pharmaceuticals.

InChI:InChI=1/C9H12BrNO2S/c1-7(2)11-14(12,13)9-5-3-8(10)4-6-9/h3-7,11H,1-2H3

Upstream product

• 108-20-3 di-isopropyl ether 
• 701-34-8 4-bromo-benzenesulfonic acid amide 
• 67-63-0 isopropyl alcohol 
• 75-31-0 isopropylamine 
• 98-58-8 4-bromobenzenesulfonyl chloride 

Downstream Products

• 1572928-52-9 N-(1-methylethyl)-4-(2-(1-propyn-1-yl)-1-piperazinyl)benzenesulfonamide 
• 1572928-53-0 tert-butyl (5-((4-(4-((1-methylethyl)sulfamoyl)phenyl)-3-(1-propyn-1-yl)-1-piperazinyl)sulfonyl)-2-pyridinyl)carbamate 
• 1572927-77-5 4-(2S)-(4-((6-amino-3-pyridinyl)sulfonyl)-2-(1-propyn-1-yl)-1-piperazinyl)-N-(1-methylethyl)benzenesulfonamide 
• 1572927-78-6 4-(2R)-(4-((6-amino-3-pyridinyl)sulfonyl)-2-(1-propyn-1-yl)-1-piperazinyl)-N-(1-methylethyl)benzenesulfonamide 
• 1572928-51-8 benzyl 4-(4-((1-methylethyl)-sulfamoyl)phenyl)-3-(1-propyn-1-yl)-1-piperazinecarboxylate 
• 1572927-76-4 4-(4-((6-amino-3-pyridinyl)sulfonyl)-2-(1-propyn-1-yl)-1-piperazinyl)-N-(1-methylethyl)benzenesulfonamide 

Relevant articles and documents

NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT

The present invention relates to a novel compound showing leukotriene B4 receptor 2 (BLT2) inhibitory activity and a pharmaceutical composition, for preventing or treating inflammatory diseases, comprising same as an active ingredient. The inventors identified a novel compound containing BTL2 inhibitory activity, and experimentally confirmed that the present novel compound had an excellent effect on the enhancement of the cancer cell death, on the inhibition of the metastasis and chemotactic mobility, and on the anti-asthma activity. Therefore, the present novel compound can be used as a very effective pharmaceutical component for treating the inflammatory-related diseases.

Synthesis of nitromethyl-substituted oxindole derivatives via a desulfonylation cascade

A cascade reaction giving nitromethyl-substituted oxindole derivatives was developed. The reaction used NaNO2 as the nitro source and potassium peroxydisulfate as an oxidant. This reaction proceeded via a radical mechanism involving substitution-desulfonlylation-cyclization steps in one pot and afforded good yields under mild conditions without using toxic metal catalysts. The resultant nitromethyl-substituted oxindole derivatives are convenient and valuable structures for different derivative syntheses.

Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 3. Structure-activity relationships within the aryl carbinol region of the N-arylsulfonamido-N′-arylpiperazine series

We have recently reported a novel approach to increase cytosolic glucokinase (GK) levels through the binding of a small molecule to its endogenous inhibitor, glucokinase regulatory protein (GKRP) these initial investigations culminated in the identification of 2-(4-((2S)-4-((6-amino-3- pyridinyl)sulfonyl)-2-(1-propyn-1-yl)-1-piperazinyl)phenyl)-1,1,1,3,3, 3-hexafluoro-2-propanol (1, AMG-3969), a compound that effectively enhanced GK translocation and reduced blood glucose levels in diabetic animals. Herein we report the results of our expanded SAR investigations that focused on modifications to the aryl carbinol group of this series. Guided by the X-ray cocrystal structure of compound 1 bound to hGKRP, we identified several potent GK-GKRP disruptors bearing a diverse set of functionalities in the aryl carbinol region. Among them, sulfoximine and pyridinyl derivatives 24 and 29 possessed excellent potency as well as favorable PK properties. When dosed orally in db/db mice, both compounds significantly lowered fed blood glucose levels (up to 58%).